Shanxi Zhendong PharmaceuticalLtd Past Earnings Performance
Past criteria checks 0/6
Shanxi Zhendong PharmaceuticalLtd has been growing earnings at an average annual rate of 6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 5.1% per year.
Key information
6.0%
Earnings growth rate
6.0%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | -5.1% |
Return on equity | -0.6% |
Net Margin | -0.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Shanxi Zhendong PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,200 | -28 | 1,547 | 204 |
31 Mar 24 | 3,457 | -20 | 1,638 | 181 |
31 Dec 23 | 3,626 | -44 | 1,741 | 191 |
30 Sep 23 | 3,713 | -77 | 1,773 | 191 |
30 Jun 23 | 3,936 | -61 | 1,850 | 177 |
31 Mar 23 | 3,791 | -61 | 1,825 | 175 |
01 Jan 23 | 3,729 | -51 | 1,793 | 178 |
30 Sep 22 | 3,841 | 2,319 | 1,935 | 194 |
30 Jun 22 | 4,173 | 2,421 | 2,126 | 222 |
31 Mar 22 | 4,689 | 2,529 | 2,415 | 223 |
01 Jan 22 | 5,094 | 2,617 | 2,653 | 219 |
30 Sep 21 | 5,528 | 378 | 2,782 | 161 |
30 Jun 21 | 5,520 | 365 | 2,864 | 151 |
31 Mar 21 | 5,196 | 299 | 2,740 | 149 |
31 Dec 20 | 4,848 | 262 | 2,576 | 136 |
30 Sep 20 | 4,653 | 208 | 2,594 | 177 |
30 Jun 20 | 4,401 | 154 | 2,435 | 172 |
31 Mar 20 | 4,445 | 152 | 2,482 | 163 |
31 Dec 19 | 4,399 | 143 | 2,492 | 145 |
30 Sep 19 | 4,155 | -67 | 2,430 | 168 |
30 Jun 19 | 3,772 | -133 | 2,305 | 134 |
31 Mar 19 | 3,546 | -147 | 2,132 | 128 |
31 Dec 18 | 3,420 | -147 | 2,078 | 123 |
30 Sep 18 | 3,746 | 120 | 2,116 | 122 |
30 Jun 18 | 3,738 | 233 | 1,956 | 151 |
31 Mar 18 | 3,786 | 295 | 1,828 | 131 |
31 Dec 17 | 3,732 | 302 | 1,632 | 118 |
30 Sep 17 | 3,702 | 343 | 1,398 | 44 |
30 Jun 17 | 3,777 | 330 | 1,327 | 0 |
31 Mar 17 | 3,504 | 243 | 1,260 | 0 |
31 Dec 16 | 3,283 | 203 | 1,182 | 0 |
30 Sep 16 | 2,688 | 117 | 1,037 | 0 |
30 Jun 16 | 2,383 | 67 | 933 | 0 |
31 Mar 16 | 2,323 | 67 | 908 | 0 |
31 Dec 15 | 2,262 | 65 | 920 | 0 |
30 Sep 15 | 2,165 | 51 | 809 | 0 |
30 Jun 15 | 2,199 | 43 | 832 | 0 |
31 Mar 15 | 2,010 | 40 | 794 | 0 |
31 Dec 14 | 1,919 | 42 | 765 | 0 |
30 Sep 14 | 1,673 | 56 | 760 | 0 |
30 Jun 14 | 1,711 | 70 | 725 | 0 |
31 Mar 14 | 1,695 | 68 | 703 | 0 |
31 Dec 13 | 1,658 | 74 | 695 | 0 |
30 Sep 13 | 1,630 | 85 | 689 | 0 |
Quality Earnings: 300158 is currently unprofitable.
Growing Profit Margin: 300158 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300158 is unprofitable, but has reduced losses over the past 5 years at a rate of 6% per year.
Accelerating Growth: Unable to compare 300158's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300158 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Return on Equity
High ROE: 300158 has a negative Return on Equity (-0.63%), as it is currently unprofitable.